[{"id":"11565097-46a7-40c4-bd2e-84aac455986c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01638533","created_at":"2021-01-18T07:02:41.766Z","updated_at":"2025-02-25T14:33:33.086Z","phase":"Phase 1","brief_title":"Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction","source_id_and_acronym":"NCT01638533","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ER • AFP","pipe":"","alterations":" ","tags":["ER • AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Istodax (romidepsin)"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 08/03/2012","start_date":" 08/03/2012","primary_txt":" Primary completion: 11/29/2018","primary_completion_date":" 11/29/2018","study_txt":" Completion: 09/01/2020","study_completion_date":" 09/01/2020","last_update_posted":"2025-02-07"},{"id":"02fe09dd-fb6d-428c-8c55-0af77e346e1c","acronym":"PTCL13","url":"https://clinicaltrials.gov/study/NCT02223208","created_at":"2025-02-26T10:03:50.822Z","updated_at":"2025-02-26T10:03:50.822Z","phase":"Phase 1/2","brief_title":"Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas","source_id_and_acronym":"NCT02223208 - PTCL13","lead_sponsor":"Fondazione Italiana Linfomi - ETS","biomarkers":" TET2","pipe":" | ","alterations":" TET2 mutation","tags":["TET2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TET2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • etoposide IV • prednisone • Istodax (romidepsin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 89","initiation":"Initiation: 09/01/2014","start_date":" 09/01/2014","primary_txt":" Primary completion: 10/01/2020","primary_completion_date":" 10/01/2020","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-12-09"},{"id":"cb1a79b5-e061-4b3c-834a-601d77043b7b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02512497","created_at":"2021-01-18T12:08:16.611Z","updated_at":"2025-02-25T14:35:44.470Z","phase":"Phase 1","brief_title":"Romidepsin Maintenance After Allogeneic Stem Cell Transplantation","source_id_and_acronym":"NCT02512497","lead_sponsor":"Ohio State University Comprehensive Cancer Center","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Istodax (romidepsin) • fludarabine IV • busulfan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 12/08/2017","start_date":" 12/08/2017","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-10-29"},{"id":"879fd467-51b3-46e4-9863-a9475f8f4f72","acronym":"Oracle","url":"https://clinicaltrials.gov/study/NCT03593018","created_at":"2021-01-18T17:39:39.095Z","updated_at":"2025-02-25T14:27:18.930Z","phase":"Phase 3","brief_title":"Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL","source_id_and_acronym":"NCT03593018 - Oracle","lead_sponsor":"The Lymphoma Academic Research Organisation","biomarkers":" PD-1 • BCL6 • CXCL13 • ICOS • MME","pipe":" | ","alterations":" PD-1 expression","tags":["PD-1 • BCL6 • CXCL13 • ICOS • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • azacitidine • bendamustine • Istodax (romidepsin) • Onureg (azacitidine oral)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 86","initiation":"Initiation: 11/09/2018","start_date":" 11/09/2018","primary_txt":" Primary completion: 02/10/2021","primary_completion_date":" 02/10/2021","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-10-09"},{"id":"5c8406ae-f056-4f83-9353-3927df966f6e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04774068","created_at":"2021-02-26T12:55:20.808Z","updated_at":"2024-07-02T16:35:06.559Z","phase":"Phase 1","brief_title":"Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas","source_id_and_acronym":"NCT04774068","lead_sponsor":"Walter Hanel","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 positive","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Istodax (romidepsin) • parsaclisib (INCB50465)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 5","initiation":"Initiation: 09/01/2021","start_date":" 09/01/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-01"},{"id":"e1b1beee-8596-4e66-9c4b-6af0006c827e","acronym":"RV-CL-PTCL-PI-003974","url":"https://clinicaltrials.gov/study/NCT02232516","created_at":"2021-01-18T10:28:31.078Z","updated_at":"2025-02-25T14:34:54.612Z","phase":"Phase 2","brief_title":"Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma","source_id_and_acronym":"NCT02232516 - RV-CL-PTCL-PI-003974","lead_sponsor":"Northwestern University","biomarkers":" ALK • CD20 • CD8 • TNFRSF8 • PAX5 • CD4 • NCAM1 • CD5 • CXCL13 • GZMB • MME • CD7 • UBR5","pipe":" | ","alterations":" ALK negative","tags":["ALK • CD20 • CD8 • TNFRSF8 • PAX5 • CD4 • NCAM1 • CD5 • CXCL13 • GZMB • MME • CD7 • UBR5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Istodax (romidepsin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/11/2015","start_date":" 06/11/2015","primary_txt":" Primary completion: 08/11/2020","primary_completion_date":" 08/11/2020","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2024-04-10"},{"id":"9e88e211-5abf-4d40-9698-3dcf80cf1326","acronym":"","url":"https://clinicaltrials.gov/study/NCT02616965","created_at":"2021-01-18T12:42:57.122Z","updated_at":"2025-02-25T14:35:59.973Z","phase":"Phase 1","brief_title":"A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma","source_id_and_acronym":"NCT02616965","lead_sponsor":"Fox Chase Cancer Center","biomarkers":" TNFRSF8 • CD4","pipe":" | ","alterations":" TNFRSF8 positive","tags":["TNFRSF8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Adcetris (brentuximab vedotin) • Istodax (romidepsin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 02/22/2017","start_date":" 02/22/2017","primary_txt":" Primary completion: 02/20/2023","primary_completion_date":" 02/20/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-02-28"},{"id":"12ddc080-e745-4e7a-8cb7-c71a05930964","acronym":"NCI-2018-00810","url":"https://clinicaltrials.gov/study/NCT03534180","created_at":"2021-01-18T17:24:34.331Z","updated_at":"2024-07-02T16:35:32.608Z","phase":"Phase 2","brief_title":"Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma","source_id_and_acronym":"NCT03534180 - NCI-2018-00810","lead_sponsor":"City of Hope Medical Center","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Istodax (romidepsin)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 08/21/2018","start_date":" 08/21/2018","primary_txt":" Primary completion: 04/21/2021","primary_completion_date":" 04/21/2021","study_txt":" Completion: 07/26/2023","study_completion_date":" 07/26/2023","last_update_posted":"2023-10-19"},{"id":"62b83cb2-2d2f-4053-b684-b9e12bf6ab81","acronym":"","url":"https://clinicaltrials.gov/study/NCT01908777","created_at":"2021-01-18T08:36:12.485Z","updated_at":"2024-07-02T16:35:44.211Z","phase":"Phase 2","brief_title":"A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT01908777","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • etoposide IV • carmustine • Istodax (romidepsin) • melphalan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 07/16/2013","start_date":" 07/16/2013","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-06-30"},{"id":"8d23040c-eb5b-46ae-b239-6ec3069ea4b5","acronym":"SEPION","url":"https://clinicaltrials.gov/study/NCT04257448","created_at":"2021-01-18T20:41:34.546Z","updated_at":"2025-02-25T14:29:02.158Z","phase":"Phase 1/2","brief_title":"Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer","source_id_and_acronym":"NCT04257448 - SEPION","lead_sponsor":"GWT-TUD GmbH","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • gemcitabine • lenalidomide • azacitidine • albumin-bound paclitaxel • Istodax (romidepsin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 05/25/2020","start_date":" 05/25/2020","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 03/01/2024","study_completion_date":" 03/01/2024","last_update_posted":"2023-05-01"},{"id":"c727cb8d-0ac6-4249-a749-71a430241ed8","acronym":"","url":"https://clinicaltrials.gov/study/NCT02393794","created_at":"2021-01-18T11:25:05.438Z","updated_at":"2025-02-25T14:35:23.787Z","phase":"Phase 1/2","brief_title":"Cisplatin Plus Romidepsin \u0026 Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)","source_id_and_acronym":"NCT02393794","lead_sponsor":"Priyanka Sharma","biomarkers":" BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • Istodax (romidepsin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 07/17/2015","start_date":" 07/17/2015","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2023-04-27"},{"id":"30169c73-ee48-439b-93a1-9446ac4506b8","acronym":"","url":"https://clinicaltrials.gov/study/NCT01796002","created_at":"2021-01-18T07:56:55.667Z","updated_at":"2024-07-02T16:35:57.846Z","phase":"Phase 3","brief_title":"Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma","source_id_and_acronym":"NCT01796002","lead_sponsor":"The Lymphoma Academic Research Organisation","biomarkers":" ALK • CD8 • CD4","pipe":" | ","alterations":" ALK negative","tags":["ALK • CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • Istodax (romidepsin)"],"overall_status":"Completed","enrollment":" Enrollment 421","initiation":"Initiation: 01/01/2013","start_date":" 01/01/2013","primary_txt":" Primary completion: 12/13/2019","primary_completion_date":" 12/13/2019","study_txt":" Completion: 12/13/2022","study_completion_date":" 12/13/2022","last_update_posted":"2023-01-10"},{"id":"aa427175-54cc-421c-9eb3-20e2eec8ad01","acronym":"","url":"https://clinicaltrials.gov/study/NCT03703375","created_at":"2021-01-18T18:08:54.175Z","updated_at":"2024-07-02T16:36:00.520Z","phase":"Phase 3","brief_title":"Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma","source_id_and_acronym":"NCT03703375","lead_sponsor":"Celgene","biomarkers":" PD-1 • BCL6 • CXCL13 • ICOS • MME","pipe":"","alterations":" ","tags":["PD-1 • BCL6 • CXCL13 • ICOS • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Istodax (romidepsin) • Onureg (azacitidine oral)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 11/06/2018","start_date":" 11/06/2018","primary_txt":" Primary completion: 02/10/2021","primary_completion_date":" 02/10/2021","study_txt":" Completion: 02/29/2024","study_completion_date":" 02/29/2024","last_update_posted":"2022-11-14"},{"id":"a60a9098-0d9a-49ad-a3a2-71b073f9778a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02512172","created_at":"2021-01-29T07:10:33.387Z","updated_at":"2025-02-25T14:35:43.892Z","phase":"Phase 1","brief_title":"A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer","source_id_and_acronym":"NCT02512172","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" CD4","pipe":" | ","alterations":" TILs","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • azacitidine • Istodax (romidepsin) • Onureg (azacitidine oral)"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 02/19/2016","start_date":" 02/19/2016","primary_txt":" Primary completion: 11/20/2021","primary_completion_date":" 11/20/2021","study_txt":" Completion: 11/20/2021","study_completion_date":" 11/20/2021","last_update_posted":"2022-03-22"},{"id":"3007d24d-b701-4281-811c-e9519c678927","acronym":"","url":"https://clinicaltrials.gov/study/NCT00426764","created_at":"2021-01-18T01:30:15.460Z","updated_at":"2024-07-02T16:36:50.177Z","phase":"Phase 2","brief_title":"A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma","source_id_and_acronym":"NCT00426764","lead_sponsor":"Celgene","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Istodax (romidepsin)"],"overall_status":"Completed","enrollment":" Enrollment 131","initiation":"Initiation: 06/19/2007","start_date":" 06/19/2007","primary_txt":" Primary completion: 11/11/2010","primary_completion_date":" 11/11/2010","study_txt":" Completion: 05/17/2018","study_completion_date":" 05/17/2018","last_update_posted":"2020-02-11"},{"id":"01bcc80b-5d58-47f6-9247-0c68750a5cf2","acronym":"","url":"https://clinicaltrials.gov/study/NCT01324323","created_at":"2021-01-18T05:23:33.157Z","updated_at":"2024-07-02T16:36:53.238Z","phase":"Phase 1","brief_title":"Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer","source_id_and_acronym":"NCT01324323","lead_sponsor":"Celgene","biomarkers":" ER","pipe":"","alterations":" ","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Istodax (romidepsin) • rifampicin"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 04/01/2011","start_date":" 04/01/2011","primary_txt":" Primary completion: 02/01/2012","primary_completion_date":" 02/01/2012","study_txt":" Completion: 03/01/2012","study_completion_date":" 03/01/2012","last_update_posted":"2019-11-25"},{"id":"7774a5db-3b1e-4979-915f-926d61069a96","acronym":"","url":"https://clinicaltrials.gov/study/NCT01324310","created_at":"2021-01-18T05:23:32.918Z","updated_at":"2024-07-02T16:36:53.250Z","phase":"Phase 1","brief_title":"Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer","source_id_and_acronym":"NCT01324310","lead_sponsor":"Celgene","biomarkers":" ER","pipe":"","alterations":" ","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Istodax (romidepsin)"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 04/01/2011","start_date":" 04/01/2011","primary_txt":" Primary completion: 01/01/2012","primary_completion_date":" 01/01/2012","study_txt":" Completion: 01/01/2012","study_completion_date":" 01/01/2012","last_update_posted":"2019-11-25"},{"id":"302775e0-230f-4e7e-9d9a-f514e4da5457","acronym":"","url":"https://clinicaltrials.gov/study/NCT01456039","created_at":"2021-01-18T06:02:49.820Z","updated_at":"2024-07-02T16:37:02.931Z","phase":"Phase 1/2","brief_title":"A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL)","source_id_and_acronym":"NCT01456039","lead_sponsor":"Celgene","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Istodax (romidepsin)"],"overall_status":"Completed","enrollment":" Enrollment 51","initiation":"Initiation: 12/01/2011","start_date":" 12/01/2011","primary_txt":" Primary completion: 07/28/2015","primary_completion_date":" 07/28/2015","study_txt":" Completion: 12/14/2018","study_completion_date":" 12/14/2018","last_update_posted":"2019-02-11"},{"id":"396316cf-b663-4dd0-81ce-d6e47945f737","acronym":"","url":"https://clinicaltrials.gov/study/NCT01897012","created_at":"2021-01-18T08:30:51.764Z","updated_at":"2024-07-02T16:37:03.460Z","phase":"Phase 1","brief_title":"Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas","source_id_and_acronym":"NCT01897012","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MYC • BCL2","pipe":" | ","alterations":" MYC positive","tags":["MYC • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Istodax (romidepsin) • alisertib (MLN8237)"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 07/17/2013","start_date":" 07/17/2013","primary_txt":" Primary completion: 10/31/2018","primary_completion_date":" 10/31/2018","study_txt":" Completion: 11/30/2018","study_completion_date":" 11/30/2018","last_update_posted":"2019-01-28"},{"id":"0403cf76-c7e6-4f6c-a247-7eed3bde6936","acronym":"","url":"https://clinicaltrials.gov/study/NCT00963274","created_at":"2021-01-18T03:45:04.401Z","updated_at":"2024-07-02T16:37:11.296Z","phase":"Phase 1","brief_title":"Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","source_id_and_acronym":"NCT00963274","lead_sponsor":"Virginia Commonwealth University","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive • ALK negative","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • Istodax (romidepsin)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 04/26/2010","start_date":" 04/26/2010","primary_txt":" Primary completion: 07/17/2014","primary_completion_date":" 07/17/2014","study_txt":" Completion: 04/13/2018","study_completion_date":" 04/13/2018","last_update_posted":"2018-04-23"},{"id":"564eeec7-b71d-41f9-b374-bbbc85756521","acronym":"","url":"https://clinicaltrials.gov/study/NCT02281279","created_at":"2021-01-18T10:44:41.914Z","updated_at":"2024-07-02T16:37:29.865Z","phase":"Phase 1/2","brief_title":"Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT02281279","lead_sponsor":"Mayo Clinic","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • Istodax (romidepsin)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 10/01/2020","primary_completion_date":" 10/01/2020","study_txt":"","study_completion_date":"","last_update_posted":"2016-08-11"}]